Cellex Cell Professionals, a Germany-based Contract Development and Manufacturing Organisation (CDMO), on Monday reported continued success in its partnership with Gift of Life Biologics, a supplier of cellular starting materials in the US.
Established in 2022, the partnership focuses on supplying tailored cellular starting materials for cell and gene therapy (CGT) manufacturing. It supports research, clinical and commercial production by meeting complex donor specifications.
Gift of Life Biologics provides customised cellular materials from its FDA HCT/P registered and EMA GMP certified facility in the United States. These materials serve as the foundation for Cellex Cell Professionals' CDMO operations in Germany.
Cellex Cell Professionals, with over a decade of CGT experience, leverages this partnership to meet strict regulatory and therapeutic demands. While Cellex operates its own collection centre and donor network, the collaboration with Gift of Life Biologics enables the company to fulfil highly specialised donor requirements for its clients.
The two companies plan to expand their collaboration to support future innovation and global CGT advancements.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option